Literature DB >> 25274961

The baseline serum value of α-amylase is a significant predictor of distance running performance.

Giuseppe Lippi, Gian Luca Salvagno, Elisa Danese, Cantor Tarperi, Antonio La Torre, Gian Cesare Guidi, Federico Schena.   

Abstract

BACKGROUND: This study was planned to investigate whether serum α-amylase concentration may be associated with running performance, physiological characteristics and other clinical chemistry analytes in a large sample of recreational athletes undergoing distance running.
METHODS: Forty-three amateur runners successfully concluded a 21.1 km half-marathon at 75%-85% of their maximal oxygen uptake (VO2max). Blood was drawn during warm up and 15 min after conclusion of the run.
RESULTS: After correction for body weight change, significant post-run increases were observed for serum values of alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, bilirubin, creatine kinase (CK), iron, lactate dehydrogenase (LDH), triglycerides, urea and uric acid, whereas the values of body weight, glomerular filtration rate, total and low density lipoprotein-cholesterol were significantly decreased. The concentration of serum α-amylase was unchanged. In univariate analysis, significant associations with running performance were found for gender, VO2max, training regimen and pre-run serum values of α-amylase, CK, glucose, high density lipoprotein-cholesterol, LDH, urea and uric acid. In multivariate analysis, only VO2max (p=0.042) and baseline α-amylase (p=0.021) remained significant predictors of running performance. The combination of these two variables predicted 71% of variance in running performance. The baseline concentration of serum α-amylase was positively correlated with variation of serum glucose during the trial (r=0.345; p=0.025) and negatively with capillary blood lactate at the end of the run (r=-0.352; p=0.021).
CONCLUSIONS: We showed that the baseline serum α-amylase concentration significantly and independently predicts distance running performance in recreational runners.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25274961     DOI: 10.1515/cclm-2014-0850

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  6 in total

Review 1.  Low serum amylase and obesity, diabetes and metabolic syndrome: A novel interpretation.

Authors:  Kei Nakajima
Journal:  World J Diabetes       Date:  2016-03-25

2.  Whey Protein Improves Marathon-Induced Injury and Exercise Performance in Elite Track Runners.

Authors:  Wen-Ching Huang; Yung-Cheng Chang; Yi-Ming Chen; Yi-Ju Hsu; Chi-Chang Huang; Nai-Wen Kan; Sheng-Shih Chen
Journal:  Int J Med Sci       Date:  2017-06-22       Impact factor: 3.738

3.  A combination of routine blood analytes predicts fitness decrement in elderly endurance athletes.

Authors:  Helmuth Haslacher; Franz Ratzinger; Thomas Perkmann; Delgerdalai Batmyagmar; Sonja Nistler; Thomas M Scherzer; Elisabeth Ponocny-Seliger; Alexander Pilger; Marlene Gerner; Vanessa Scheichenberger; Michael Kundi; Georg Endler; Oswald F Wagner; Robert Winker
Journal:  PLoS One       Date:  2017-05-05       Impact factor: 3.240

4.  Impact of different running distances on muscle and lymphocyte DNA damage in amateur marathon runners.

Authors:  Jae Hoon Ryu; Il Young Paik; Jin Hee Woo; Ki Ok Shin; Su Youn Cho; Hee Tae Roh
Journal:  J Phys Ther Sci       Date:  2016-02-29

5.  Middle-distance running acutely influences the concentration and composition of serum bile acids: Potential implications for cancer risk?

Authors:  Elisa Danese; Gian Luca Salvagno; Cantor Tarperi; Davide Negrini; Martina Montagnana; Luca Festa; Fabian Sanchis-Gomar; Federico Schena; Giuseppe Lippi
Journal:  Oncotarget       Date:  2017-04-18

6.  Sympatho-adrenergic activation by endurance exercise: Effect on metanephrines spillover and its role in predicting athlete's performance.

Authors:  Elisa Danese; Cantor Tarperi; Gian Luca Salvagno; Alessandra Guzzo; Fabian Sanchis-Gomar; Luca Festa; Luciano Bertinato; Martina Montagnana; Federico Schena; Giuseppe Lippi
Journal:  Oncotarget       Date:  2018-02-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.